Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

GeoVax Labs (GOVX) Research & Development (2016 - 2025)

GeoVax Labs (GOVX) has disclosed Research & Development for 16 consecutive years, with $5.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development fell 31.87% to $5.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $22.7 million, a 1.77% increase, with the full-year FY2024 number at $23.7 million, up 14.44% from a year prior.
  • Research & Development was $5.0 million for Q3 2025 at GeoVax Labs, up from $4.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $12.9 million in Q4 2021 to a low of $602783.0 in Q1 2021.
  • A 5-year average of $4.4 million and a median of $4.4 million in 2024 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: skyrocketed 1602.55% in 2021, then crashed 70.8% in 2022.
  • GeoVax Labs' Research & Development stood at $12.9 million in 2021, then plummeted by 70.8% to $3.8 million in 2022, then surged by 65.59% to $6.2 million in 2023, then rose by 22.04% to $7.6 million in 2024, then crashed by 33.71% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for GOVX's Research & Development are $5.0 million (Q3 2025), $4.7 million (Q2 2025), and $5.4 million (Q1 2025).